Clinical trials: Urological Disease
Hyperphosphatemia, End Stage Renal Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT04456803
- Testing
- Ferric citrate tablet, Sevelamer carbonate tablet
- Where
- 20 sites in China
- Volunteers
- 239 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
Atrophic Vaginitis
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo.
- Trial name
- NCT02195986
- Testing
- Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream
- Where
- 21 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
Urinary Incontinence
Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence Products
The purpose of this post market clinical investigation is to demonstrate the performance and safety of the TENA SmartCare Change Indicator.
- Trial name
- NCT04846270
- Testing
- TENA SmartCare Change Indicator
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Essity Hygiene and Health AB
Overactive Bladder
A Safety Extension Study of DR-OXY-301
This is a safety extension study of DR-OXY-301 at pre-selected sites. Subjects who complete the DR-OXY-301 study are eligible to participate. The duration of this extension study will be up to approximately 42 weeks.
- Trial name
- NCT00782769
- Testing
- Oxybutinyn Vaginal Ring 4mg, Oxybutinyn Vaginal Ring 6mg
- Where
- 35 sites in United States
- Volunteers
- 240 people
- Sponsor
- Duramed Research
Stress Urinary Incontinence
Solace Stress Urinary inContinence Control Efficacy and Safety Study
The SUCCESS Trial is designed to determine whether the Solace Bladder Control System is safe and effective for the treatment of Stress Urinary Incontinence (SUI) in adult females.
- Trial name
- SUCCESS (NCT02210273)
- Testing
- Solace Bladder Control (Vesair) Balloon
- Where
- 20 sites in United States
- Volunteers
- 221 people
- Sponsor
- Solace Therapeutics, Inc.
Hematuria - Cause Not Known
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
This study includes adult patients who see a urologist because of blood in their urine. The amount is so small it can only be seen with a microscope. This is called microhematuria. There can be many reasons for microhematuria.
- Trial name
- CREDIBLE (NCT06394869)
- Testing
- Cxbladder Triage Plus
- Where
- 20 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Pacific Edge Limited
Chronic Kidney Disease
A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
This research study is designed to assess the safety and effectiveness of an experimental drug called PRT-201 in patients both receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing…
- Trial name
- NCT02110901
- Testing
- PRT-201
- Where
- 35 sites in United States
- Volunteers
- 349 people
- Sponsor
- Proteon Therapeutics
Anemia of Chronic Kidney Disease
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal…
- Trial name
- NCT01971164
- Testing
- JTZ-951
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Shionogi Inc.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
- Trial name
- NCT06747572
- Where
- 45 sites in United States, Belgium and 7 more
- Volunteers
- 401 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Urinary Bladder, Overactive
Pharmacokinetics and Relative Bioavailability Study
A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules
- Trial name
- NCT01521767
- Testing
- tolterodine tartrate
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Kidney Disease
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.
- Trial name
- NCT01683409
- Testing
- Baricitinib
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Renal Insufficiency
Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients
The objective of the trial is to investigate the effect of different degrees of renal impairment on the pharmacokinetics and safety of the combination of BI 207127 and faldaprevir after 3 days of dosing (BI 207127 bid…
- Trial name
- NCT01957657
- Testing
- BI 207127, faldaprevir
- Where
- Germany
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Polycystic Liver Disease
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of CAM2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic PLD, either isolated as in autosomal dominant PLD…
- Trial name
- POSITANO (NCT05281328)
- Testing
- CAM2029
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 71 people
- Sponsor
- Camurus AB
Anemia, Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis
This prospective observational study will assess the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in clinical practice in patients with chronic kidney disease, in pre-dialysis or on dialysis…
- Trial name
- NCT01309295
- Where
- Albania
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal
The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.
- Trial name
- NCT05168436
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Bristol-Myers Squibb
Hyperphosphatemia, End Stage Renal Disease
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
The purpose of the study is to determine the effect and optimum dose and evaluate the safety of ferric citrate, administered three times daily (TID) immediately after meals for a total daily dose of 4 or 6 grams for 56 days, on…
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT01503736
- Testing
- ferric citrate
- Where
- 5 sites in Taiwan
- Volunteers
- 183 people
- Sponsor
- Panion & BF Biotech Inc.
Anemia, Renal Failure, Chronic Renal Failure
Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
The purpose of the study is to assess the effect of an early and complete correction of anemia after treatment with epoetin alfa on the rate of progression of chronic renal failure (which involves improper functioning of the…
- Trial name
- NCT00312871
- Testing
- Epoetin alfa
- Volunteers
- 217 people
- Sponsor
- Janssen Cilag S.A.S.
COVID-19, Infectious Disease
Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture
The aim of this cohort study is to validate Viture®, a continuous temperature telemonitoring system, evaluating the level of agreement with a standard commercially available digital axillary thermometer.
- Conditions
- COVID-19, Infectious Disease, Tract Infection, Urinary, Bacteremia
- Trial name
- Viture (NCT05959928)
- Testing
- Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely
- Where
- Spain
- Volunteers
- 208 people
- Sponsor
- Vitio Medical S.L.
Urinary Bladder Neoplasms
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC
The purpose of the study is to investigate the safety, tolerability, and preliminary efficacy of the monoclonal bispecific trifunctional antibody Catumaxomab in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT04819399
- Testing
- Catumaxomab
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Lindis Biotech GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.